KEGG   DRUG: Zanidatamab
Entry
D12011                      Drug                                   
Name
Zanidatamab (USAN/INN);
Zanidatamab-hrii;
Ziihera (TN)
Product
Formula
C5553H8526N1482O1726S36
Exact mass
124739.4891
Mol weight
124816.41
Sequence
(Heavy chain)
GEVQLVESGG GLVQPGGSLR LSCAASGFTF ADYTMDWVRQ APGKGLEWVG DVNPNSGGSI
YNQRFKGRFT FSVDRSKNTL YLQMNSLRAE DTAVYYCARN LGPSFYFDYW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYVYPPSRDE
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFALV SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPG
(Light chain)
GDIQMTQSPS SLSASVGDRV TITCKASQDV SIGVAWYQQK PGKAPKLLIY SASYRYTGVP
SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ QYYIYPATFG QGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(heavy chain)
GDIQMTQSPS SLSASVGDRV TITCRASQDV NTAVAWYQQK PGKAPKLLIY SASFLYSGVP
SRFSGSRSGT DFTLTISSLQ PEDFATYYCQ QHYTTPPTFG QGTKVEIKGG SGGGSGGGSG
GGSGGGSGEV QLVESGGGLV QPGGSLRLSC AASGFNIKDT YIHWVRQAPG KGLEWVARIY
PTNGYTRYAD SVKGRFTISA DTSKNTAYLQ MNSLRAEDTA VYYCSRWGGD GFYAMDYWGQ
GTLVTVSSAA EPKSSDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN
KALPAPIEKT ISKAKGQPRE PQVYVLPPSR DELTKNQVSL LCLVKGFYPS DIAVEWESNG
QPENNYLTWP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP
G
(Disulfide bride: H23-H97, H147-H203, H223-L215, H229-h261, H232-h264, H264-H324, H370-H428, h24-h89, h150-h224, h296-h356, h402-h460, L24-L89, L135-L195)
  Type
Peptide
Remark
ATC code: L01FD07
Product: D12011<US>
Efficacy
Antineoplastic
  Disease
Biliary tract cancer (HER2 positive) [DS:H00046 H00047]
  Type
Monoclonal antibody
Target
ERBB2 (HER2, CD340) [HSA:2064] [KO:K05083]
  Pathway
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
     L01FD07 Zanidatamab
      D12011  Zanidatamab (USAN/INN) <US>
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2 (HER2, CD340)
     D12011  Zanidatamab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12011
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12011
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12011
Other DBs
CAS: 2169946-15-8
PubChem: 497620424
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system